Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 6.33B 5.54B 5.1B 4.73B 8.98B 601B 9.13B 61.2B 23.8B 296B 23.76B 23.24B 1,025B P/E 2026 *
71.5x
P/E 2027 * 37.8x
Enterprise Value 6.33B 5.54B 5.1B 4.73B 8.98B 601B 9.13B 61.2B 23.8B 296B 23.76B 23.24B 1,025B EV / Sales 2026 *
21.8x
EV / Sales 2027 * 16.8x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week+1.06%
Current month+1.06%
1 month+34.78%
3 months+55.74%
6 months+59.75%
Current year+68.95%
1 week 308.76
Extreme 308.76
323.3
1 month 237
Extreme 237
323.3
Current year 175.89
Extreme 175.89
323.3
1 year 116.44
Extreme 116.44
323.3
3 years 49.24
Extreme 49.24
323.3
5 years 49.24
Extreme 49.24
323.3
10 years 49.24
Extreme 49.24
323.3
Manager TitleAgeSince
Chief Executive Officer 66 2022-12-04
Director of Finance/CFO 56 2022-10-31
Director of Finance/CFO 47 2015-05-20
Director TitleAgeSince
Chairman 76 2003-02-28
Director/Board Member 76 2011-01-31
Director/Board Member 66 2008-08-03
Date Insider Type Main position Quantity % Market Cap.
06-15Fiscal year

Director

6,435 0.0321%
06-11Fiscal year

Director

14,461 0.0722%
06-10Sell

Director

-4,500 0.0225%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+1.06%+180.79%+358.62% 6.35B
+2.96%+3.01%+59.87%+173.31% 1,070B
+3.05%+5.23%+72.11%+67.81% 624B
-0.04%+1.20%+35.72%+87.93% 450B
-2.58%-2.07%+27.62%+22.57% 328B
+1.36%+0.17%+29.90%+49.33% 284B
+1.98%+4.08%-25.78%-39.02% 217B
+0.45%+1.65%+25.65%+68.35% 198B
+5.21%+7.93%+21.99%+83.23% 161B
+1.48%-0.04%-4.64%-32.25% 135B
Average +0.74%+1.59%+42.32%+83.99% 347.38B
Weighted average by Cap. +1.49%+1.63%+42.10%+87.84%

Financials

2026 *2027 *
Net sales 290M 254M 234M 217M 412M 27.54B 418M 2.81B 1.09B 13.59B 1.09B 1.07B 46.98B 376M 329M 303M 281M 533M 35.65B 542M 3.63B 1.41B 17.59B 1.41B 1.38B 60.81B
Net income 94.91M 83.05M 76.54M 70.94M 135M 9.01B 137M 918M 357M 4.45B 356M 349M 15.37B 182M 159M 147M 136M 259M 17.3B 263M 1.76B 685M 8.54B 684M 669M 29.5B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Employees
47
Date Price Change Volume
26-07-07 US$319.43 -0.31% 316,467
26-07-06 US$320.42 +0.27% 349,436
26-07-02 US$319.55 +2.42% 368,156
26-07-01 US$312.01 -1.29% 521,622
26-06-30 US$316.09 +0.65% 879,068
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
319.43USD
Average target price
277.60USD
Spread / Average Target
-13.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock